27 February 2007 Pharmacokinetic study of a systemically administered novel liposomal Temoporfin formulation in an animal tumor model
Author Affiliations +
Abstract
Meso-tetra(hydroxyphenyl)chlorin (mTHPC)(international generic name Temoporfin) is a potent photosensitizer used for photodynamic therapy (PDT). In this study the pharmacokinetics of a systemically administered novel lipid formulation of Temoporfin in a murine tumor model has been investigated. Fluorescence spectroscopy measurements were performed at several time intervals following drug administration, yielding information on the Temoporfin concentration within excised internal organs as a function of time after injection. Both point-monitoring and imaging setups were used. The acquired fluorescence data were correlated to the concentration of Temoporfin obtained with High Performance Liquid Chromatography (HPLC). There was a significant correlation between the fluorescence methods and HPLC for most organs investigated. The pharmacokinetics of this new liposomal formulation of Temoporfin exhibited a rather flat temporal profile in the time interval 2-8 hours in this study.
© (2007) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Jenny Svensson, Jenny Svensson, Ann Johansson, Ann Johansson, Niels Bendsoe, Niels Bendsoe, Susanna Gräfe, Susanna Gräfe, Tilmann Trebst, Tilmann Trebst, Stefan Andersson-Engels, Stefan Andersson-Engels, Katarina Svanberg, Katarina Svanberg, } "Pharmacokinetic study of a systemically administered novel liposomal Temoporfin formulation in an animal tumor model", Proc. SPIE 6427, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVI, 64270T (27 February 2007); doi: 10.1117/12.698932; https://doi.org/10.1117/12.698932
PROCEEDINGS
8 PAGES


SHARE
Back to Top